Literature DB >> 34260280

Adeno-associated Virus 9 Structural Rearrangements Induced by Endosomal Trafficking pH and Glycan Attachment.

Judit J Penzes1, Paul Chipman1, Nilakshee Bhattacharya2, Allison Zeher3, Rick Huang3, Robert McKenna1, Mavis Agbandje-McKenna1.   

Abstract

Adeno-associated viruses (AAVs) are small nonenveloped single-stranded DNA (ssDNA) viruses that are currently being developed as gene therapy biologics. After cell entry, AAVs traffic to the nucleus using the endo-lysosomal pathway. The subsequent decrease in pH triggers conformational changes to the capsid that enable the externalization of the capsid protein (VP) N termini, including the unique domain of the minor capsid protein VP1 (VP1u), which permits the phospholipase activity required for the capsid lysosomal egress. Here, we report the AAV9 capsid structure, determined at the endosomal pHs (7.4, 6.0, 5.5, and 4.0), and terminal galactose-bound AAV9 capsids at pHs 7.4 and 5.5 using cryo-electron microscopy and three-dimensional image reconstruction. Taken together, these studies provide insight into AAV9 capsid conformational changes at the 5-fold pore during endosomal trafficking, in both the presence and absence of its cellular glycan receptor. We visualized, for the first time, that acidification induces the externalization of the VP3 and possibly VP2 N termini, presumably in prelude to the externalization of VP1u at pH 4.0, which is essential for lysosomal membrane disruption. In addition, the structural study of AAV9-galactose interactions demonstrates that AAV9 remains attached to its glycan receptor at the late endosome pH 5.5. This interaction significantly alters the conformational stability of the variable region I of the VPs, as well as the dynamics associated with VP N terminus externalization. IMPORTANCE There are 13 distinct Adeno-associated virus (AAV) serotypes that are structurally homologous and whose capsid proteins (VP1 to -3) are similar in amino acid sequence. However, AAV9 is one of the most commonly studied and is used as a gene therapy vector. This is partly because AAV9 is capable of crossing the blood-brain barrier and readily transduces a wide array of tissues, including the central nervous system. In this study, we provide AAV9 capsid structural insight during intracellular trafficking. Although the AAV capsid has been shown to externalize the N termini of its VPs, to enzymatically disrupt the lysosome membrane at low pH, there was no structural evidence to confirm this. By utilizing AAV9 as our model, we provide the first structural evidence that the externalization process occurs at the protein interface at the icosahedral 5-fold symmetry axis and can be triggered by lowering the pH.

Entities:  

Keywords:  AAV9; adeno-associated virus; cryoEM; endosomal trafficking; gene therapy; glycan attachment; parvovirus; receptors; structural virology; vesicular trafficking

Mesh:

Substances:

Year:  2021        PMID: 34260280      PMCID: PMC8428384          DOI: 10.1128/JVI.00843-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  93 in total

1.  Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.

Authors:  Chiara F Valori; Ke Ning; Matthew Wyles; Richard J Mead; Andrew J Grierson; Pamela J Shaw; Mimoun Azzouz
Journal:  Sci Transl Med       Date:  2010-06-09       Impact factor: 17.956

2.  AAV capsid structure and cell interactions.

Authors:  Mavis Agbandje-McKenna; Jürgen Kleinschmidt
Journal:  Methods Mol Biol       Date:  2011

Review 3.  AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy.

Authors:  Rithu Pattali; Yongchao Mou; Xue-Jun Li
Journal:  Gene Ther       Date:  2019-06-26       Impact factor: 5.250

4.  PHENIX: a comprehensive Python-based system for macromolecular structure solution.

Authors:  Paul D Adams; Pavel V Afonine; Gábor Bunkóczi; Vincent B Chen; Ian W Davis; Nathaniel Echols; Jeffrey J Headd; Li-Wei Hung; Gary J Kapral; Ralf W Grosse-Kunstleve; Airlie J McCoy; Nigel W Moriarty; Robert Oeffner; Randy J Read; David C Richardson; Jane S Richardson; Thomas C Terwilliger; Peter H Zwart
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

5.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

6.  Infectious molecular clones of adeno-associated virus isolated directly from human tissues.

Authors:  Bruce C Schnepp; Ryan L Jensen; K Reed Clark; Philip R Johnson
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

Review 7.  The cryptic life style of adeno-associated virus.

Authors:  K I Berns; R M Linden
Journal:  Bioessays       Date:  1995-03       Impact factor: 4.345

8.  AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6.

Authors:  Jérôme Denard; Jérémy Rouillon; Thibaut Leger; Camille Garcia; Michele P Lambert; Graziella Griffith; Christine Jenny; Jean-Michel Camadro; Luis Garcia; Fedor Svinartchouk
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-08       Impact factor: 6.698

Review 9.  Twenty-Five Years of Structural Parvovirology.

Authors:  Mario Mietzsch; Judit J Pénzes; Mavis Agbandje-McKenna
Journal:  Viruses       Date:  2019-04-20       Impact factor: 5.048

10.  Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy.

Authors:  Andrew Lloyd; Natalia Piglowska; Thomas Ciulla; Sarah Pitluck; Scott Johnson; Marric Buessing; Thomas O'Connell
Journal:  Br J Ophthalmol       Date:  2019-01-18       Impact factor: 4.638

View more
  6 in total

Review 1.  Cryo-electron Microscopy of Adeno-associated Virus.

Authors:  Scott M Stagg; Craig Yoshioka; Omar Davulcu; Michael S Chapman
Journal:  Chem Rev       Date:  2022-05-16       Impact factor: 72.087

2.  Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity.

Authors:  Mario Mietzsch; Joshua A Hull; Victoria E Makal; Alberto Jimenez Ybargollin; Jennifer C Yu; Kedrick McKissock; Antonette Bennett; Judit Penzes; Bridget Lins-Austin; Qian Yu; Paul Chipman; Nilakshee Bhattacharya; Duncan Sousa; David Strugatsky; Peter Tijssen; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2022-05-09       Impact factor: 6.549

3.  Structural basis for the neurotropic AAV9 and the engineered AAVPHP.eB recognition with cellular receptors.

Authors:  Guangxue Xu; Ran Zhang; Huapeng Li; Kaixin Yin; Xinyi Ma; Zhiyong Lou
Journal:  Mol Ther Methods Clin Dev       Date:  2022-05-29       Impact factor: 5.849

4.  A new perspective on the evolution and diversity of the genus Amdoparvovirus (family Parvoviridae) through genetic characterization, structural homology modeling, and phylogenetics.

Authors:  Marta Canuti; Judit J Pénzes; Andrew S Lang
Journal:  Virus Evol       Date:  2022-06-17

5.  Adeno-associated virus type 2 (AAV2) uncoating is a stepwise process and is linked to structural reorganization of the nucleolus.

Authors:  Sereina O Sutter; Anouk Lkharrazi; Elisabeth M Schraner; Kevin Michaelsen; Anita Felicitas Meier; Jennifer Marx; Bernd Vogt; Hildegard Büning; Cornel Fraefel
Journal:  PLoS Pathog       Date:  2022-07-11       Impact factor: 7.464

6.  Structural basis of receptor usage by the engineered capsid AAV-PHP.eB.

Authors:  Seongmin Jang; Hao K Shen; Xiaozhe Ding; Timothy F Miles; Viviana Gradinaru
Journal:  Mol Ther Methods Clin Dev       Date:  2022-07-31       Impact factor: 5.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.